Company news

Youcare Pharmaceutical Group Co. Ltd. Class A (SSE:688658) news

Youcare Pharmaceutical Group Co. Ltd. Class A news releases on 6ix. Latest, Sep 15, 2026: "Youcare Pharmaceutical Group Co., Ltd."Announcement on Opening…

Youcare Pharmaceutical Group Co. Ltd. Class A (SSE:688658) news

Press releases & updates

"Youcare Pharmaceutical Group Co., Ltd."Announcement on Opening a Raised Funds Account and Signing a Supervision Agreement for Deposit of Raised Funds in Special Account

"Youcare Pharmaceutical Group Co., Ltd."Announcement on the Use of a Portion of Over-raised Funds for Investment in New Projects

"Youcare Pharmaceutical Group Co., Ltd."Announcement on Voluntary Disclosure of the Subsidiary's Receipt of FDA Clinical Trial Approval for YKYY033 Injection

"Youcare Pharmaceutical Group Co., Ltd."Announcement on Voluntary Disclosure of Obtaining Clinical Trial Approval from NMPA for New Indication of YKYY017 Inhalation Aerosol

"Youcare Pharmaceutical Group Co., Ltd."Announcement on the Unfreezing of Shares of the Controlling Shareholder

"Youcare Pharmaceutical Group Co., Ltd."Announcement on Voluntary Disclosure of Obtaining Clinical Trial Approval from NMPA for New Indication of Subsidiary's YKYY033 Injection

Announcement on Voluntary Disclosure of YKYY017 Aerosol Inhalation Formulation Receiving FDA Clinical Trial Approval for the Indication of Prophylaxis and Treatment of Coronavirus-Associated Respiratory Infections

Announcement on Voluntary Disclosure of Withdrawal of Drug Registration Application by a Subsidiary

Announcement on Unfreezing of Partial Shares Held by Controlling Shareholders

Announcement on Completing the Transfer Registration in Judicial Auction of Partial Shares Held by Controlling Shareholders

Announcement on Investment in Construction Project

Report for Q1 2026

Announcement on Opening a Raised Fund Account and Signing a Raised Fund Account Storage Supervision Agreement

Announcement on Progress in the 2nd Judicial Auction of a Portion of Company Shares Held by the Controlling Shareholder

Announcement on Voluntary Disclosure of Subsidiary’s YKYY025 Injection Obtaining Clinical Trial Approval from the National Medical Products Administration

Announcement on Resolutions of the 2025 Annual General Meeting

Announcement on Voluntary Disclosure of Obtaining Clinical Trial Approval from the National Medical Products Administration for the Indications for the Treatment and Prevention of Human Bronchovirus Infection by the YKYY018 Inhalation Aerosol of Subsidiary

Announcement on Voluntary Disclosure of FDA Clinical Trial Approval for the Indication of YKYY018 Nebulized Inhalation for the Treatment and Prevention of Human Parainfluenza Virus Infection by Subsidiary

Announcement on Changing and Closing Some Investment Projects Financed by Raised Funds and Using Residual Raised Funds to Add Investment Projects Financed by Raised Funds and Permanently Supplement Current Capital

Announcement on the Failure of Judicial Auction of Partial Shares Held by Controlling Shareholders

Announcement on Preliminary Earnings Estimate for 2025

Indicative Announcement on Judicial Auction of Some Shares Held by Controlling Shareholders

Announcement on Resignation of Director and Senior Management Member and Election of Employee Director

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

Announcement on Expected Loss in Performance for 2025

Notice on Convening the 1st Extraordinary General Meeting in 2026

Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025

Announcement on Voluntary Disclosure of Subsidiary’s YKYY032 Injection Obtaining Clinical Trial Approval from the National Medical Products Administration and FDA

Announcement on Voluntary Disclosure of Subsidiary’s YKYY031 Injection Obtaining Clinical Trial Approval from the National Medical Products Administration

Announcement on Appointment of an Additional Director and Adjustment of Members of Special Committees of the Board of Directors

Announcement on Voluntary Disclosure of Subsidiary’s YKYY018 Inhalation Aerosol Obtaining Clinical Trial Approval from the National Medical Products Administration

Announcement on Voluntary Disclosure of Subholding YKYY018 Inhalation Aerosol's FDA Clinical Trial Approval

Announcement on Completing Term Change and Election of Board of Directors and Appointing Senior Management Members and Securities Affairs Representative

Announcement on Voluntary Disclosure of Subsidiary’s YKYY013 Injection Obtaining Clinical Trial Approval from the National Medical Products Administration

Notice on Convening the 2nd Extraordinary General Meeting in 2025

Announcement on Voluntary Disclosure of Subsidiary’s YKYY013 Injection Obtaining Clinical Trial Approval from the FDA

Announcement on Resignation of Independent Director

Announcement on Convening the 2025 Semi-annual Performance Briefing

Indicative Announcement on Completion of Transfer Registration for Partial Shares Held by Controlling Shareholders Subject to Judicial Auction and Change in Equity Shares Exceeding Integer Multiple of 5%

Announcement on Voluntary Disclosure of Subsidiary’s YKYY029 Injection Obtaining Clinical Trial Approval from the FDA

Announcement on Voluntary Disclosure of Subsidiary’s YKYY029 Injection Obtaining Clinical Trial Approval from the National Medical Products Administration

Announcement on Progress of the 2nd Judicial Auction of a Portion of Company Shares Held by the Controlling Shareholder

Indicative Announcement on the 2nd Judicial Auction of Some Shares Held by Controlling Shareholder

Announcement on the Results of Shareholding Increase by Actual Controllers and Directors

Announcement on Reply to Inquiry Letter of 2024 Annual Report from Shanghai Stock Exchange

Announcement on Voluntary Disclosure of Ganciclovir for Injection Passing Consistency Evaluation of Quality and Efficacy of Generic Drugs

Announcement on Resolution of the 2024 Annual General Meeting

Announcement on 2024 Annual Profit Distribution Plan

Announcement on Preliminary Earnings Estimate for 2024

Announcement on Voluntary Disclosure of FDA Approval for Clinical Trial of the Subsidiary's YKYY025 Injection